Akash test for clone

Test article to check the clone issue

 
• By akash
  
Generate a summary of this article
Listen to this article
Beta

Test article to check the clone issue

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Pink Sheet

Pink Sheet Podcast: Understanding the US FDA’s CDER Leadership - Clone

 
• By Mary Jo Laffler

Pink Sheet reporter and editors discuss the likely impacts of Center for Drug Evaluation and Research Director Richard Pazdur’s retirement from the FDA and Tracy Beth Høeg becoming the center’s acting director.

Test FDA Voucher Program Approvals Will Come From Product Centers, But Ambiguity Lingers - Clone

 
• By Sue Sutter

Approval decisions for the FDA's CNPV pilot program will be made by product center officials, but it's unclear if the responsibility lies with center directors or review office leaders.

Pink Sheet Podcast: Understanding the US FDA’s CDER Leadership

 
• By Mary Jo Laffler

Pink Sheet reporter and editors discuss the likely impacts of Center for Drug Evaluation and Research Director Richard Pazdur’s retirement from the FDA and Tracy Beth Høeg becoming the center’s acting director.

Test FDA Voucher Program Approvals Will Come From Product Centers, But Ambiguity Lingers

 
• By Sue Sutter

It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.

More from Distribution/Supply Chain

Working With The Inspectors: UK’s eXmoor Gets License To Make ATMPs

 
• By Eliza Slawther

It is “absolutely fundamental” that manufacturers of cell and gene therapies interact with inspectors from regulatory agencies to understand their expectations around good manufacturing practice, a compliance consultant at CDMO eXmoor pharma says.

EU Helps Firms To Prioritize Submission Of Data On ‘Critical’ Drugs

 
• By Ian Schofield

The submission of data for products on a new list of critical medicines is “a first step in achieving complete standardized product information for all medicines in the EU,” says the EMA.

EU To Launch New Platform For Tackling Shortages Of ‘Critical’ Medicines In Health Crises

 
• By Ian Schofield

The ESMP will have dedicated secure spaces for companies and national agencies to provide data on the supply situation for critical medicines both under normal circumstances and in crisis situations.